{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:33:42Z","timestamp":1786984422928,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"NCATS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"DFG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.aohep.2025.102143","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T15:22:09Z","timestamp":1761146529000},"page":"102143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Alpha-1 antitrypsin Pi*MZ variant increases the risk of liver disease progression in MASLD and MASH"],"prefix":"10.1016","volume":"31","author":[{"given":"Bradley","family":"Jermy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Brownrigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Strnad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.aohep.2025.102143_bib0001","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.aohep.2025.102143_bib0002","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstr\u00f6m","year":"2017","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2025.102143_bib0003","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.aohep.2025.102143_bib0004","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2025.102143_bib0005","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.aohep.2025.102143_bib0006","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.cmet.2024.03.011","article-title":"New and emerging treatments for metabolic dysfunction-associated steatohepatitis","volume":"36","author":"Tincopa","year":"2024","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.aohep.2025.102143_bib0007","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cmet.2019.12.002","article-title":"Leveraging human genetics to identify potential new treatments for fatty liver disease","volume":"31","author":"Romeo","year":"2020","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.aohep.2025.102143_bib0008","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/hep.23759","article-title":"The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease","volume":"52","author":"Rotman","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.aohep.2025.102143_bib0009","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2016.03.011","article-title":"PNPLA3 gene in liver diseases","volume":"65","author":"Tr\u00e9po","year":"2016","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2025.102143_bib0010","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jhep.2020.04.003","article-title":"Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort\u2606","volume":"73","author":"Anstee","year":"2020","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2025.102143_bib0011","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/gutjnl-2020-323729","article-title":"Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency","volume":"71","author":"Fromme","year":"2022","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.aohep.2025.102143_bib0012","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/apt.17967","article-title":"New developments in biomarkers and clinical drug development in alpha-1 antitrypsin deficiency-related liver disease","volume":"59","author":"Loomba","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.aohep.2025.102143_bib0013","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1053\/j.gastro.2020.04.058","article-title":"Liver phenotypes of European adults heterozygous or homozygous for Pi\u2217Z variant of AAT (Pi\u2217MZ vs Pi\u2217ZZ genotype) and noncarriers","volume":"159","author":"Schneider","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2025.102143_bib0014","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/gutjnl-2018-316228","article-title":"Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis","volume":"68","author":"Strnad","year":"2019","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.aohep.2025.102143_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2022.102066","article-title":"Alpha-1-antitrypsin Pi*MZ variant increases risk of developing hepatic events in nonalcoholic fatty liver disease patients","volume":"47","author":"Murali","year":"2023","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"12","key":"10.1016\/j.aohep.2025.102143_bib0016","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.aohep.2025.102143_bib0017","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/hep.31726","article-title":"Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement","volume":"74","author":"Hagstr\u00f6m","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.aohep.2025.102143_bib0018","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2337\/dc21-1953","article-title":"Glucagon-like peptide 1 receptor agonists and sodium\u2013glucose cotransporter 2 inhibitors and risk of nonalcoholic fatty liver disease among patients with type 2 diabetes","volume":"45","author":"Pradhan","year":"2022","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.aohep.2025.102143_bib0019","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","article-title":"Can we use old NAFLD data under the new MASLD definition?","volume":"80","author":"Song","year":"2024","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2025.102143_bib0020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser B"},{"issue":"6","key":"10.1016\/j.aohep.2025.102143_bib0021","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2205416","article-title":"Fazirsiran for liver disease associated with alpha1-antitrypsin deficiency","volume":"387","author":"Strnad","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.aohep.2025.102143_bib0022","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/j.2040-4603.2013.tb00527.x","article-title":"Broad spectrum of hepatocyte inclusions in humans, animals, and experimental models","volume":"3","author":"Strnad","year":"2011","journal-title":"Compr Physiol"},{"issue":"1","key":"10.1016\/j.aohep.2025.102143_bib0023","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMra010772","article-title":"Alpha1-antitrypsin deficiency\u2014A model for conformational diseases","volume":"346","author":"Carrell","year":"2002","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.aohep.2025.102143_bib0024","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nrendo.2016.124","article-title":"Endoplasmic reticulum proteostasis in hepatic steatosis","volume":"12","author":"Baiceanu","year":"2016","journal-title":"Nature Rev Endocrinol"},{"issue":"5988","key":"10.1016\/j.aohep.2025.102143_bib0025","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1126\/science.1190354","article-title":"An autophagy-enhancing drug promotes degradation of mutant \u03b11-antitrypsin Z and reduces hepatic fibrosis","volume":"329","author":"Hidvegi","year":"2010","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.aohep.2025.102143_bib0026","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.aohep.2025.102143_bib0027","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/j.cgh.2024.05.052","article-title":"Genetics of metabolic dysfunction-associated steatotic liver disease: the state of art update","volume":"22","author":"Sookoian","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2025.102143_bib0028","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1056\/NEJMc2402341","article-title":"Phase 1 trials of PNPLA3 siRNA in I148M homozygous patients with MAFLD","volume":"391","author":"Fabbrini","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.aohep.2025.102143_bib0029","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2022.11.025","article-title":"A phase I\/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis","volume":"78","author":"Mak","year":"2023","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.aohep.2025.102143_bib0030","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/j.soard.2016.06.004","article-title":"PNPLA3 p. I148M variant is associated with greater reduction of liver fat content after bariatric surgery","volume":"12","author":"Krawczyk","year":"2016","journal-title":"Surg Obes Relat Dis"},{"issue":"6","key":"10.1016\/j.aohep.2025.102143_bib0031","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.jacl.2018.08.003","article-title":"Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: a double-blind, randomized, placebo-controlled study","volume":"12","author":"Oscarsson","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"9","key":"10.1016\/j.aohep.2025.102143_bib0032","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/aje\/kwx246","article-title":"Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population","volume":"186","author":"Fry","year":"2017","journal-title":"Am J Epidemiol"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268125003680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268125003680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:53:52Z","timestamp":1780649632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268125003680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1665268125003680"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2025.102143","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alpha-1 antitrypsin Pi*MZ variant increases the risk of liver disease progression in MASLD and MASH","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2025.102143","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"102143"}}